CMMB Chemomab Therapeutics Ltd

Price (delayed)

$1.16

Market cap

$16.49M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.56

Enterprise value

$12.14M

Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need. Based on the unique and pivotal role of ...

Highlights
CMMB's EPS is up by 43% year-on-year and by 24% since the previous quarter
CMMB's net income is up by 38% year-on-year and by 20% since the previous quarter
The debt has soared by 120% YoY
CMMB's equity has plunged by 52% YoY and by 22% from the previous quarter

Key stats

What are the main financial stats of CMMB
Market
Shares outstanding
14.22M
Market cap
$16.49M
Enterprise value
$12.14M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.24
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$19.36M
EBITDA
N/A
Free cash flow
N/A
Per share
EPS
-$1.56
Free cash flow per share
N/A
Book value per share
$0.94
Revenue per share
$0
TBVPS
$1.27
Balance sheet
Total assets
$18.01M
Total liabilities
$4.68M
Debt
$390,000
Equity
$13.33M
Working capital
$12.44M
Liquidity
Debt to equity
0.03
Current ratio
3.83
Quick ratio
3.83
Net debt/EBITDA
N/A
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-83.7%
Return on equity
-109.9%
Return on invested capital
-202.5%
Return on capital employed
-142.2%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CMMB stock price

How has the Chemomab Therapeutics stock price performed over time
Intraday
2.65%
1 week
6.42%
1 month
26.09%
1 year
-14.07%
YTD
127.45%
QTD
26.09%

Financial performance

How have Chemomab Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$20.46M
Net income
-$19.34M
Gross margin
N/A
Net margin
N/A
CMMB's net income is up by 38% year-on-year and by 20% since the previous quarter
Chemomab Therapeutics's operating income has increased by 37% YoY and by 20% from the previous quarter

Growth

What is Chemomab Therapeutics's growth rate over time

Valuation

What is Chemomab Therapeutics stock price valuation
P/E
N/A
P/B
1.24
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
CMMB's EPS is up by 43% year-on-year and by 24% since the previous quarter
CMMB's price to book (P/B) is 107% more than its last 4 quarters average of 0.6 and 13% more than its 5-year quarterly average of 1.1
CMMB's equity has plunged by 52% YoY and by 22% from the previous quarter

Efficiency

How efficient is Chemomab Therapeutics business performance
Chemomab Therapeutics's return on invested capital has shrunk by 70% YoY but it has increased by 24% QoQ
CMMB's return on equity is down by 41% year-on-year but it is up by 3.6% since the previous quarter
The return on assets has declined by 23% year-on-year but it has increased by 5% since the previous quarter

Dividends

What is CMMB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CMMB.

Financial health

How did Chemomab Therapeutics financials performed over time
CMMB's total assets is down by 49% year-on-year and by 19% since the previous quarter
The total liabilities has declined by 34% year-on-year and by 9% since the previous quarter
The debt is 97% lower than the equity
CMMB's debt to equity has soared by 200% YoY and by 50% from the previous quarter
The debt has soared by 120% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.